Focus: Rezolute is a public-stage biotechnology company focused on biologics for rare metabolic and oncology indications, headquartered in Redwood City, CA. The company operates at a clinical-stage scale with a focused pipeline in hyperinsulinism and diabetic macular edema.
Profile data last refreshed 8h ago · AI intelligence enriched 2mo ago
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Rezolute is a clinical-stage rare-disease biotech with meaningful Phase 3 catalysts and recent financing relief, but carries inherent pre-launch execution risk and limited organizational stability for risk-averse candidates.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Rezolute
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Rezolute's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Xeris Biopharma Holdings, Inc. (XERS) (CIK 0001867096) — EX-99.1
EX-99.1
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth - Streetwise Reports
Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth Streetwise Reports
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data - Streetwise Reports
Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data Streetwise Reports
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD) The Globe and Mail
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? - TradingView
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week? TradingView
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - Social Flow Trades - newser.com
Why Rezolute (RZLT) valuation makes sense when you dig deeper (Ticks Up) 2026-05-08 - Social Flow Trades newser.com
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo